TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

NATACYN

NATAMYCIN
Ophthalmology Approved 1978-10-30
1
Indication
--
Phase 3 Trials
1
Priority Reviews
47
Years on Market

Details

Status
Prescription
First Approved
1978-10-30
Routes
OPHTHALMIC
Dosage Forms
SUSPENSION

Companies

Active Ingredient: NATAMYCIN

NATACYN Approval History

Loading approval history...

What NATACYN Treats

4 indications

NATACYN is approved for 4 conditions since its original approval in 1978. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Fungal Blepharitis
  • Conjunctivitis
  • Keratitis
  • Fusarium Solani Keratitis
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

NATACYN FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

: NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthal...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.